Expert Interview
Discussing the standard of care and/or the potential of Vabysmo (faricimab-svoa) and the recent label expansion approved by the FDA to include treatment of RVO
Ticker(s): RHHBY, REGNInstitution: UT Health
- Ophthalmologist with clinical interest in corneal diseases, corneal surgery, and cataract surgery.
- Currently manages 140-150 patients with RVO per year.
- Familiar with the two phase 3 trials (BALATON and COMINO), which formed the basis of the FDA’s decision to expand the label for Vabysmo to include RVO.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
